Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rose 2.2% during trading on Monday . The company traded as high as $67.93 and last traded at $67.46, with a volume of 386,468 shares. The stock had previously closed at $66.00.

RARE has been the subject of a number of analyst reports. Jefferies Group set a $109.00 price target on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Monday, August 1st. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 12th. Canaccord Genuity reaffirmed a “buy” rating and set a $120.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Thursday, June 16th. Wedbush reaffirmed an “outperform” rating and set a $92.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, June 28th. Finally, Bank of America Corp. began coverage on Ultragenyx Pharmaceutical in a research note on Tuesday, June 28th. They set a “buy” rating and a $72.00 target price for the company. Three investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Ultragenyx Pharmaceutical has an average rating of “Buy” and an average target price of $99.10.

The stock’s market capitalization is $2.69 billion. The company has a 50 day moving average of $58.90 and a 200 day moving average of $61.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.02. During the same quarter in the prior year, the firm posted ($0.83) earnings per share. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post ($5.93) EPS for the current fiscal year.

In other Ultragenyx Pharmaceutical news, insider Sunil Agarwal sold 649 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total value of $34,189.32. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, July 15th. The shares were sold at an average price of $50.85, for a total value of $1,017,000.00. Following the completion of the transaction, the chief executive officer now owns 513,597 shares in the company, valued at $26,116,407.45. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently made changes to their positions in RARE. Schwab Charles Investment Management Inc. increased its position in shares of Ultragenyx Pharmaceutical by 8.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 153,788 shares of the biopharmaceutical company’s stock valued at $17,252,000 after buying an additional 11,497 shares during the period. Dimensional Fund Advisors LP boosted its stake in Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock valued at $6,414,000 after buying an additional 5,139 shares in the last quarter. Jennison Associates LLC boosted its stake in Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock valued at $84,739,000 after buying an additional 109,724 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $1,010,000.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.